MIMIX BIOTHERAPEUTICS
mimiX Biotherapeutics aims to deliver the next generation biofabrication technology, that will enable tissue manufacturing for therapeutic and diagnostic purposes. mimiX Biotherapeutics will make this vision a reality by providing an ultra-fast biomanufacturing technology capable of creating point-of-care patient-specific biological tissue equivalents for regenerative, personalized, and precision medicine.
MIMIX BIOTHERAPEUTICS
Social Links:
Industry:
Biotechnology Health Diagnostics Manufacturing Therapeutics
Founded:
2019-08-30
Address:
Neuchâtel, Neuchatel, Switzerland
Country:
Switzerland
Website Url:
http://www.mimixbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
10 K CHF
Technology used in webpage:
Wix Hosted
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Recensa Therapeutics
Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.
Current Employees Featured
Founder
Investors List
Venture Kick
Venture Kick investment in Grant - MimiX Biotherapeutics
Official Site Inspections
http://www.mimixbio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "MimiX Biotherapeutics"
Home - IMMIX BIOPHARMA INC
Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and immune-mediated …See details»
About Us - IMMIX BIOPHARMA INC
ImmixBio was founded in 2012 by a driven physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent expert and an impact-driven founding family office.See details»
About Us – Meet The Team - IMMIX BIOPHARMA INC
Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and select immune …See details»
Immix Biopharma (Nasdaq: IMMX) - LinkedIn
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases.See details»
Immix Biopharma - Crunchbase Company Profile
Contact Email [email protected] Phone Number (888) 958-1084 Immix Biopharma is a biotech company that develops treatments for cancer and other inflammation-driven diseases.See details»
Immix Biopharma | Drug Discovery News
ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office.See details»
U.S. Food and Drug Administration Approves Immix Biopharma
Jan 3, 2022 · Rare Pediatric Disease Designation (“RPDD”) qualifies Immix Biopharma to receive fast track review, and a priority review voucher (“PRV”) at the time of marketing approval of …See details»
Immix Biopharma - Edison Group
Nov 21, 2024 · Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain …See details»
Immix Biopharma Announces 100% Overall Response …
LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...See details»
Immix Biopharma - Overview, News & Similar companies - ZoomInfo
Sep 14, 2023 · Immix Biopharma contact info: Phone number: (310) 651-8041 Website: www.immixbio.com What does Immix Biopharma do? Immix Biopharma is a clinical-stage bio …See details»
The Science - IMMIX BIOPHARMA INC
Our N-GENIUS platform, with EXPAND technology, has produced our pioneering lead candidate, CAR-T NXC-201, which has demonstrated an enhanced tolerability profile with the potential to …See details»
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data …
Apr 15, 2024 · Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other …See details»
IMMIX BIOPHARMA, INC. - IPOScoop
We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)TM in oncology and inflammation. Our lead product candidate, IMX-110, …See details»
Immix Biopharma Announces Positive NXC-201 - GlobeNewswire
Oct 5, 2024 · Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other …See details»
Immix Biopharma - Craft
Oct 29, 2024 · Immix Biopharma is a biopharmaceutical company developing therapies for cancer patients. It offers Imx-110, a combination therapy designed to inhibit cancer resistance and …See details»
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela …
Oct 26, 2023 · Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq:IMMX), is a Los Angeles, California based clinical-stage biopharmaceutical company engaged in the discovery …See details»
ImmixBio Announces Clinical Trial and Supply Agreement with …
Aug 27, 2021 · ImmixBio ™ is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) ™ in oncology and inflammation. Our lead asset, …See details»
Immix Biopharma Announces Closing of $15 Million Public …
Feb 8, 2024 · Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing cell therapies in autoimmune disease.See details»
West LA-Based Biotech ImmixBio - Maker of Cancer Treatments
On July 23rd, 2021 DotLA reported, ImmixBio, a West L.A.-based startup developing cancer therapies, announced on Friday it submitted a confidential filing to go public. Ilya Rachman, …See details»
Immix Biopharma Completes $5 Million At-The-Market Equity …
Jun 14, 2023 · Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue …See details»